Clinical Trial Update: Ruxolitinib and Steroid As First Line Therapy for Acute GVHD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib in combination with a steroid as first-line therapy for acute graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• PREDNISONE (Prednisone)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Acute GVHD | Phase 2 | Status: TERMINATED